MedPath

The Effect of Dexmedetomidine and Esketamine Combined Infusion Quality of Sleep Undergoing Modified Radical Mastectomy

Not Applicable
Recruiting
Conditions
Dexmedetomidine Plus Esketamine Affect Postoperative Sleep Quality
Interventions
Registration Number
NCT06414941
Lead Sponsor
Anqing Municipal Hospital
Brief Summary

BACKGROUND: Some studies have revealed that intravenous dexmedetomidine and esketamine improve the quality of sleep after surgery. The investigators investigated whether co-administration dexmedetomidine and esketamine could better improve the the quality of sleep after modified radical mastectomy.

METHODS: One hundred and five women with elective modified radical mastectomy were randomly divided into 3 groups: Patients in group D received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation. Patients in group DE1 received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively. Patients in group DE2 received received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively. Primary outcome was the quality of sleep (PSQI) at the day after surgery and 1 day after surgery. The secondary outcomes included MAP, HR, postoperative VAS pain scores, side effects such as the incidence of postoperative nausea and vomiting, hallucination, as well as agitation, drowness, postoperative rescue analgesics and anti-emetics, recovery time, and extubation time.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
105
Inclusion Criteria
  • American Society of Anesthesiologists (ASA) physical status Ⅰ- Ⅱ
  • Scheduled for elective modified radical mastectomy
Exclusion Criteria
  • Severe respiratory disease
  • Renal or hepatic insufficiency
  • History of preoperative psychiatric
  • Preoperative bradycardia
  • Preoperative atrioventricular block
  • Preoperative hypertension
  • BMI>30

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dexmedetomidine on sleep quality with radical mastectomyDexmedetomidine administrationDexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Dexmedetomidine plus high- dose esketamine on sleep quality with radical mastectomyDexmedetomidine plus low-dose esketamine administrationDexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Dexmedetomidine on sleep quality with radical mastectomyDexmedetomidine plus high-dose esketamine administrationDexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Dexmedetomidine plus high- dose esketamine on sleep quality with radical mastectomyDexmedetomidine administrationDexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Dexmedetomidine on sleep quality with radical mastectomyDexmedetomidine plus low-dose esketamine administrationDexmedetomidine infusion Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Dexmedetomidine plus low-dose esketamine on sleep quality with radical mastectomyDexmedetomidine administrationDexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Dexmedetomidine plus low-dose esketamine on sleep quality with radical mastectomyDexmedetomidine plus low-dose esketamine administrationDexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Dexmedetomidine plus low-dose esketamine on sleep quality with radical mastectomyDexmedetomidine plus high-dose esketamine administrationDexmedetomidine and low-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Dexmedetomidine plus high- dose esketamine on sleep quality with radical mastectomyDexmedetomidine plus high-dose esketamine administrationDexmedetomidine and high-dose eskeamine combined infusion Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Primary Outcome Measures
NameTimeMethod
Pittsburgh sleep quality index (PSQI)the day after surgery

Our primary outcome was Pittsburgh sleep quality index (PSQI) at the day after surgery

Secondary Outcome Measures
NameTimeMethod
Pittsburgh sleep quality index (PSQI)1 day after surgery

Our primary outcome was Pittsburgh sleep quality index (PSQI) on 1 day after surgery

pain visual analogue scale scoresThe first 48 hours after operation

Our primary outcome was pain visual analogue scale scores

Trial Locations

Locations (1)

Department of Anqing Hospital Anesthesiology

🇨🇳

Anqing, Anhui, China

© Copyright 2025. All Rights Reserved by MedPath